Loading...

Cara Therapeutics, Inc.

0HTC.L•LSE
Healthcare
Biotechnology
£5.33
£-0.01(-0.22%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Cara Therapeutics, Inc.'s revenue moved from $3.004M in Q4 2023 to $2.56M in Q3 2024. Operating income in Q3 2024 was -$5.99M, with a strong operating margin of -234%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Cara Therapeutics, Inc. remained robust at -$10.44M, reflecting operational efficiency. Net income rose to -$12.48M, with an EPS of -$0.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;